News - Actelion

Filter

Current filters:

Actelion

Popular Filters

18 to 42 of 60 results

Actelion's Opsumit significantly reduced risk of morbidity/mortality events

29-08-2013

Results of SERAPHIN, the pivotal study with Switzerland-based Actelion's (SIX: ATLN) macitentan (trade…

ActelionBiotechnologymacitentanOpsumitResearchRespiratory and Pulmonary

Actelion bid for Ceptaris looks secured as FDA approves Valchlor

26-08-2013

Privately-held USA-based Ceptaris Therapeutics revealed yesterday (August 26) that the US Food and Drug…

ActelionBiotechnologyCeptaris TherapeuticsDermatologicalsMergers & AcquisitionsNorth AmericaRegulationValchlor

FDA staffers back riociguat approval, but with modified dose

05-08-2013

On Tuesday (August 6), the US Food and Drug Administration's Renal Drugs Advisory Committee will discuss…

ActelionAdempasBayerNorth AmericaOpsumitPharmaceuticalRegulationRespiratory and PulmonaryriociguatTracleer

Actelion to reinforce portfolio with acquisition

01-08-2013

Through a US subsidiary, Switzerland-based Actelion (SIX: ATLN), Europe's largest biotech firm, has entered…

ActelionBiotechnologyCeptaris TherapeuticsMergers & AcquisitionsValchlor

US pulmonologists views on PAH prescribing options

19-07-2013

US pulmonologists surveyed by health care advisory firm Decision Resources consider a drug's effect on…

ActelionBayerMarkets & MarketingNorth AmericaOpsumitPharmaceuticalRespiratory and Pulmonaryriociguat

Actelion posts healthy first-quarter 2013 results, forecasts double-digit growth in 2015

16-04-2013

Switzerland-based Actelion (SIX: ATLN), Europe's largest biotech firm, today (April 16) reported first-quarter…

ActelionBiotechnologyFinancial

Japanese approval for Actelion's epoprostenol "ACT"

19-02-2013

Europe's largest biotech firm Actelion (SIX: ATLN) yesterday announced that Japan's Ministry of Health,…

ActelionAsia-PacificBiotechnologyepoprostenol "ACT"RegulationRespiratory and PulmonaryVeletri

Actelion posts strong earnings growth but flat sales for 2012

14-02-2013

Switzerland-based Actelion (SIX: ATLN), Europe's largest biotechnology firm, this morning reported 2012…

ActelionBiotechnologyFinancial

Actelion's ponesimod does well in mid-stage psoriasis trial

18-12-2012

Europe's largest biotech firm Actelion (SIX: ATLN) says that its selective S1P1 modulator, ponesimod,…

ActelionBiotechnologyImmunologicalsponesimodResearch

Actelion filing for EU approval of Opsumit accepted

23-11-2012

Switzerland-based Actelion (SIX: ATLN) says that it has submitted a Marketing Authorisation Application…

ActelionBiotechnologyEuropemacitentanOpsumitRegulationRespiratory and Pulmonary

New Zealand updates on Tracleer and sildenafil listing

21-11-2012

New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with…

ActelionArrow PharmaceuticalsAsia-PacificPharmaceuticalPricingRegulationRespiratory and PulmonarysildenafilTracleer

Actelion files for US approval of Opsumit for PAH

23-10-2012

Europe's largest biotech company Actelion (SIX: ATLN) said yesterday that it has submitted a New Drug…

ActelionBiotechnologymacitentanNorth AmericaOpsumitRegulationResearchRespiratory and Pulmonary

Actelion post sales dip for first nine months, but back in profit

18-10-2012

Switzerland's Actelion (SIX: ATLN) posted financial results for the first nine months of 2012, with product…

ActelionBiotechnologyFinancialmacitentanOpsumitResearchRespiratory and Pulmonaryselexipag

Proposal in relation to Actelion's Tracleer in New Zealand

01-10-2012

New Zealand's national pharmaceuticals funding agency PHARMAC is seeking feedback on a proposal in relation…

ActelionAsia-PacificBiotechnologyPricingRegulationRespiratory and PulmonaryTracleer

Swiss biotech Actelion implements cost saving initiative

11-09-2012

Switzerland-based Actelion (SIX: ATLN), Europe's largest biotech company, says that it has now concluded…

ActelionBiotechnologyFinancialManagement

Actelion hikes earnings outlook despite lower sales

20-07-2012

Switzerland-based Actelion (ATLN: VX), Europe's largest biotech company, reported first-half 2012 financial…

ActelionBiotechnologyFinancial

Actelion announces cost saving initiative; Ipsen to hang on to Dreux

12-07-2012

Europe largest biotech firm, Actelion (SIX: ATLN) this morning said it has launched a cost saving initiative…

ActelionBiotechnologyEuropeFinancialIpsenPharmaceutical

Auxilium and Actelion get Xiaflex approval in Canada

10-07-2012

US company Auxilium Pharmaceuticals (Nasdaq: AUXL) and the Canadian subsidiary of Actelion (SIX: ATLN),…

ActelionAuxilium PharmaceuticalsBiotechnologyNorth AmericaRare diseasesRegulationXiaflex

Actelion's macitentan meets primary endpoint in pivotal Phase III PAH study

01-05-2012

Europe's largest biotech company, Actelion (SIX: ATLN), says that initial analysis indicates that the…

ActelionBiotechnologymacitentanResearchRespiratory and Pulmonary

Actelion 1st-qtr profits slump as lead product sales slip

19-04-2012

Switzerland-based Actelion (ATLN: VX), Europe's largest biotech firm, posted first-quarter 2012 financial…

ActelionBiotechnologyFinancial

Actelion drops setipiprant, gets miglustat approval in Japan

04-04-2012

Switzerland-based Actelion Ltd (SIX: ATLN) announced says that it will re-direct its development efforts…

ActelionAsia-PacificBiotechnologyBrazavesInflammatory diseasesMiglustatRare diseasesRegulationResearchsetipiprantZavesca

18 to 42 of 60 results

Back to top